Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

  • STATUS
    Recruiting
  • End date
    Jul 11, 2023
  • participants needed
    46
  • sponsor
    Sanofi
Updated on 11 June 2021
measurable disease
dexamethasone
lenalidomide
refractory multiple myeloma
pomalidomide

Summary

Primary Objectives:

  • To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)
  • To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device
  • To evaluate the pharmacokinetics (PK) of SC and IV isatuximab

Secondary Objectives:

  • To estimate absolute bioavailability of SC and IV isatuximab
  • To measure receptor occupancy (RO) after isatuximab SC versus IV administration
  • To assess efficacy of isatuximab after SC and IV administration
  • To assess patient expectations prior to and patient experience and satisfaction after SC administration
  • To evaluate potential immunogenicity of SC or IV isatuximab

Description

Total study duration is variable depending on treatment and follow-up periods, including 21 days of screening, and treatment period until disease progression, unacceptable adverse reaction or other reason for discontinuation. End of treatment will be 30 days after last administration of investigational medicinal product, or before further anti-myeloma therapy, whichever comes first; approximately 14 months after first study treatment administration.

Details
Condition Multiple Myeloma, Lymphoproliferative Disorder, Lymphoproliferative disorders, multiple myeloma (mm)
Treatment Pomalidomide, Dexamethasone, isatuximab SAR650984
Clinical Study IdentifierNCT04045795
SponsorSanofi
Last Modified on11 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Participant must be above 18 years of age or country's legal age of majority if the legal age is >18 years old, at the time of signing the informed consent
Participant has been previously diagnosed with multiple myeloma (MM) based on standard criteria and currently requires treatment because MM has relapsed following a response, according to International Myeloma Working Group (IMWG) criteria
Participant has received at least two previous therapies including lenalidomide and a proteasome inhibitor and has demonstrated disease progression on last therapy or after completion of the last therapy
Participants with measurable disease defined as at least one of the following
Serum M protein 0.5 g/dL (5 g/L)
Urine M protein 200 mg/24 hours
Serum free light chain (FLC) assay: Involved FLC assay 10 mg/dL ( 100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65)
Male or female: Contraceptive use by men or women

Exclusion Criteria

Malignancy within 3 years prior to enrollment
Eastern Cooperative Oncology Group (ECOG) performance status score >2\
Inadequate hematological, liver or renal function
Serum calcium (corrected for albumin) level above the upper limit of normal (ULN) range
Patients with prior anti-CD38 treatment are excluded if
Refractory to anti-CD38 treatment defined as progression on or within 60 days of the last dose of the anti-CD38 or
Intolerant to the anti-CD38 previously received or
Progression after initial response on anti-CD38 therapy with a washout period inferior to 9 months before the first dose of isatuximab SC or IV
Participant did not achieve a minimal response or better to at least one of the previous lines of treatment (ie, primary refractory disease is not eligible)
Received any investigational drug within 14 days or 5 half-lives of the investigational drug, whichever is longer
Prior anti-cancer therapy within 14 days
Any >Grade 1 adverse reaction unresolved from previous treatments according to the NCI-CTCAE v5.0. The presence of alopecia or peripheral neuropathy Grade 2 without pain is allowed
Previous allogeneic stem cell transplantation with active Graft Versus Host Disease or being under immunosuppressive therapy in the last 2 months previously to the inclusion in the trial
Daily requirement for corticosteroids
Known to be HIV+ or to have hepatitis A or uncontrolled or active hepatitis B virus (HBV) infection (patients with positive HBsAg [HBsAg] and/or HBV DNA) or active HCV (HCV) infection (positive HCV RNA and negative anti-HCV)
Active tuberculosis and severe infections requiring treatment with antibiotic parenteral administration
Any clinically significant, uncontrolled medical conditions that, in the Investigator's opinion, would expose excessive risk to the patient or may interfere with compliance or interpretation of the study results
History of erythema multiforme or severe hypersensitivity to prior immunomodulatory drugs (IMiDs)
Hypersensitivity or history of intolerance to immunomodulatory drugs (IMiDs), dexamethasone, mannitol, pregelatinized starch, sodium stearyl fumarate, histidine (as base and hydrochloride salt), arginine hydrochloride, poloxamer 188, sucrose or any of the other components of study therapy that are not amenable to premedication with steroids and histamine H2 blockers or would prohibit further treatment with these agents
Inability to tolerate thromboprophylaxis
The above information is not intended to contain all considerations relevant
to a patient's potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note